Nusayba A. Bagegni

604 total citations
29 papers, 223 citations indexed

About

Nusayba A. Bagegni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Nusayba A. Bagegni has authored 29 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Nusayba A. Bagegni's work include Advanced Breast Cancer Therapies (12 papers), Cancer Treatment and Pharmacology (9 papers) and Breast Cancer Treatment Studies (8 papers). Nusayba A. Bagegni is often cited by papers focused on Advanced Breast Cancer Therapies (12 papers), Cancer Treatment and Pharmacology (9 papers) and Breast Cancer Treatment Studies (8 papers). Nusayba A. Bagegni collaborates with scholars based in United States, Malaysia and Israel. Nusayba A. Bagegni's co-authors include Foluso O. Ademuyiwa, Tao Yu, Lindsay L. Peterson, Katherine Clifton, X. Cynthia, Andrew A. Davis, Mark O. Palmier, Steven R. Van Doren, Jingqin Luo and R. Bhaskaran and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Journal of Molecular Biology.

In The Last Decade

Nusayba A. Bagegni

27 papers receiving 222 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nusayba A. Bagegni United States	9	154	104	89	47	34	29	223
Laura L. Michel Germany	9	120 0.8×	72 0.7×	60 0.7×	32 0.7×	15 0.4×	37	194
Vicente Carañana Spain	7	227 1.5×	127 1.2×	90 1.0×	22 0.5×	20 0.6×	20	262
Míriam Arumí Spain	5	113 0.7×	47 0.5×	80 0.9×	33 0.7×	14 0.4×	13	172
Jason Mouabbi United States	7	113 0.7×	100 1.0×	64 0.7×	24 0.5×	13 0.4×	41	205
Pamela Trillo Aliaga Italy	9	209 1.4×	83 0.8×	139 1.6×	69 1.5×	17 0.5×	26	291
Arielle J. Medford United States	8	139 0.9×	98 0.9×	88 1.0×	50 1.1×	15 0.4×	44	247
Coralia Bueno Spain	8	111 0.7×	63 0.6×	78 0.9×	36 0.8×	17 0.5×	22	170
Tetsuhiro Yoshinami Japan	6	116 0.8×	50 0.5×	53 0.6×	33 0.7×	12 0.4×	48	174
Luca Boscolo Bielo Italy	10	132 0.9×	79 0.8×	63 0.7×	58 1.2×	8 0.2×	27	211
Ray Manneh Kopp Spain	9	69 0.4×	44 0.4×	83 0.9×	38 0.8×	21 0.6×	35	172

Countries citing papers authored by Nusayba A. Bagegni

Since Specialization

Citations

This map shows the geographic impact of Nusayba A. Bagegni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nusayba A. Bagegni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nusayba A. Bagegni more than expected).

Fields of papers citing papers by Nusayba A. Bagegni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nusayba A. Bagegni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nusayba A. Bagegni. The network helps show where Nusayba A. Bagegni may publish in the future.

Co-authorship network of co-authors of Nusayba A. Bagegni

This figure shows the co-authorship network connecting the top 25 collaborators of Nusayba A. Bagegni. A scholar is included among the top collaborators of Nusayba A. Bagegni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nusayba A. Bagegni. Nusayba A. Bagegni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ademuyiwa, Foluso O., X. Cynthia, Katherine N. Weilbaecher, et al.. (2025). Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research. 31(11). 2173–2182. 1 indexed citations

Bagegni, Nusayba A., Karthik V. Giridhar, & Daphne Stewart. (2025). HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers. Cancers. 17(24). 4021–4021.

Kennedy, William R., Eric Laugeman, Yi Huang, et al.. (2025). Long-Term Results of a Phase 2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone-Positive Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 124(5). 1239–1247.

Clifton, Katherine, X. Cynthia, Jingqin Luo, et al.. (2024). Abstract PO5-05-05: Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer. Cancer Research. 84(9_Supplement). PO5–5. 1 indexed citations

Gerratana, Lorenzo, Katherine Clifton, Arielle J. Medford, et al.. (2023). Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer. Clinical Cancer Research. 29(16). 3092–3100. 4 indexed citations

Bagegni, Nusayba A., Leslie Nehring, Jingqin Luo, et al.. (2023). Abstract OT3-11-01: TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity. Cancer Research. 83(5_Supplement). OT3–11. 1 indexed citations

Ademuyiwa, Foluso O., Lindsay L. Peterson, Nusayba A. Bagegni, et al.. (2023). Abstract P3-06-06: Real-world analysis of adverse events of patients with triple negative breast cancer receiving therapy per KEYNOTE-522. Cancer Research. 83(5_Supplement). P3–6. 1 indexed citations

Goetz, Matthew P., Daniel G. Stover, Nusayba A. Bagegni, et al.. (2022). LBA20 Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors. Annals of Oncology. 33. S1387–S1388. 11 indexed citations

Bagegni, Nusayba A., Andrew A. Davis, Katherine Clifton, & Foluso O. Ademuyiwa. (2022). Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. Breast Cancer Targets and Therapy. Volume 14. 113–123. 19 indexed citations

10.

Bagegni, Nusayba A., Leslie Nehring, J. L. Anderson, et al.. (2022). A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 40(16_suppl). TPS1128–TPS1128. 3 indexed citations

11.

Bagegni, Nusayba A., Haeseong Park, Feng Gao, et al.. (2022). Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 89(4). 487–497. 7 indexed citations

12.

Kruse, Megan, Irene Kang, Nusayba A. Bagegni, et al.. (2021). Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncology and Therapy. 10(1). 279–289. 4 indexed citations

13.

Clifton, Katherine, Jingqin Luo, Tao Yu, et al.. (2020). Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA). Breast Cancer Research and Treatment. 185(3). 639–646. 3 indexed citations

14.

Sanjeevaiah, Aravind, Rama Suresh, Rutika Mehta, et al.. (2020). P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial. Annals of Oncology. 31. S132–S132. 1 indexed citations

15.

Rudra, Soumon, Amit Roy, Randall Brenneman, et al.. (2020). Radiation-Induced Brachial Plexopathy in Patients With Breast Cancer Treated With Comprehensive Adjuvant Radiation Therapy. Advances in Radiation Oncology. 6(1). 100602–100602. 11 indexed citations

16.

Bagegni, Nusayba A. & Lindsay L. Peterson. (2020). Age-related disparities in older women with breast cancer. Advances in cancer research. 146. 23–56. 17 indexed citations

17.

Bagegni, Nusayba A., Tao Yu, & Foluso O. Ademuyiwa. (2019). Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. PLoS ONE. 14(9). e0222358–e0222358. 36 indexed citations

18.

Park, Haeseong, Tanner M. Johanns, A. Craig Lockhart, et al.. (2019). Abstract CT212: Combining pembrolizumab with locally delivered radiation therapy for the treatment of metastatic esophageal cancer. Cancer Research. 79(13_Supplement). CT212–CT212. 1 indexed citations

19.

Bagegni, Nusayba A., Shana Thomas, Ning Liu, et al.. (2017). Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Research. 19(1). 123–123. 53 indexed citations

20.

Bhaskaran, R., Mark O. Palmier, Nusayba A. Bagegni, Xiangyang Liang, & Steven R. Van Doren. (2007). Solution Structure of Inhibitor-Free Human Metalloelastase (MMP-12) Indicates an Internal Conformational Adjustment. Journal of Molecular Biology. 374(5). 1333–1344. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact